Covid Booster Costs Spur Calls to Shift From Free Jabs for All

Bloomberg Law, April 11, 2022. The U.S. Covid-19 vaccine funding may have to shift from a model of free shots for all to one in which the government only subsidizes boosters for targeted populations, public health analysts say. Annual Covid-19 boosters for all Americans , would cost billions of dollars each year .“Given the much greater expense of Covid boosters compared to flu shots and the time needed to revise and manufacture Covid vaccines, we need to hope we won’t need annual shots,” said Diana Zuckerman, founder and president of the National Center for Health Research.

Read More »

Narrow Aduhelm Coverage Sparks Debate Over Viability of Future Treatments

Politico, April 9th, 2022. The Biden administration’s contentious decision to only partially cover Aduhelm could reach well beyond the world of Alzheimer’s drugs, potentially affecting efforts to develop treatments for devastating diseases. “it was a defining moment for the White House and they passed with flying colors,” said Diana Zuckerman, the president of the National Center for Health Research. It “has sent a message to industry and to patient groups, and also to the FDA, that the standards had gotten too loose.”

Read More »

FDA advisers to discuss ALS drug at Wednesday meeting

Politico, March 29, 2022. On March 30, FDA holds a highly anticipated advisory committee on neurological drugs to discuss a drug from Amylyx that aims to treat amyotrophic lateral sclerosis (ALS). Dr. Diana Zuckerman told Politico: “Did the FDA schedule an advisory committee meeting to placate patient advocates and other political pressure in the hope that the advisory committee would vote against it? Or is the FDA really considering approving it?”

Read More »